Clinical Trial Update: A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of PF-02545920 in psychiatrically stable subjects with schizophrenia; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-02545920

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2018-08-20